[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
November 1, 2006

Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(17):2087-2089. doi:10.1001/jama.296.17.2087-b

To the Editor: The report of the OASIS-6 trial by Yusuf and colleagues1 showed improved survival and a tendency toward decreased severe bleeding in patients treated with the factor Xa inhibitor fondaparinux compared with unfractionated heparin (UFH) therapy. These results appear even more positive when compared with another recent trial that found increased severe bleeding with enoxaparin in ST-segment elevation myocardial infarction.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×